VALVELESS IMPEDANCE PUMP DRUG DELIVERY SYSTEMS

• US 20090209945A1
• Filed: 01/19/2009
• Published: 08/20/2009
• Est. Priority Date: 01/18/2008
• Status: Abandoned Application

• Current Assignee: NeuroSystec Corporation
• Original Assignee: NeuroSystec Corporation
• Inventors: Krag, Adrian L., Pananen, Jacob E., Lobl, Thomas J., Canfield, David L., Nagy, Anna I.
• Application Number:
  US12/355,868
• Publication Number:
  US 20090209945A1
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A61M 2205/106 reciprocating
• CPC Class Codes: A61M 2205/8243 by induction
• CPC Class Codes: A61M 2205/8287 operated by an external magnetic or electromagnetic field
• CPC Class Codes: A61M 2206/20 having means for promoting or enhancing the flow, actively or passively
• CPC Class Codes: A61M 2210/0612 Eyes
• CPC Class Codes: A61M 2210/0662 Ears
• CPC Class Codes: A61M 2210/0693 Brain, cerebrum
• CPC Class Codes: A61M 5/14224 Diaphragm type
• CPC Class Codes: A61M 5/14276 specially adapted for implantation

Abstract

A drug-delivery unit suitable for implantation into a patient body may include a valveless impedance pump. In some implementations the unit may include an actuator, control electronics and a battery, and may communicate with an external patient interface unit. The patient interface unit can be used to control operation of the implant and to download data from the implant. The patient interface unit can also be used to charge the implant and/or a separate charger can be used. In other implementations, a drug-delivery implant unit may lack internal electronics and instead rely on an externally-supplied magnetic field to actuate the pump.

Claims

1. An implant unit, comprising:

a pump chamber including a flexible wall, an inlet opening and an outlet opening;

a force-transferring member configured to compress the flexible wall at an actuation position, wherein the actuation position

generally defines a first sub-chamber located between the inlet opening and the actuation position and a second sub-chamber located between the outlet opening and the actuation position, and

is located such that compression of the flexible wall at the actuation location while a fluid is in the pump chamber results in a higher fluid pressure in the first sub-chamber relative to the second sub-chamber and a net fluid flow through the pump chamber; and

a housing sized for implantation in a living human or other animal and separating an internal space containing the pump chamber and the force-transferring member from an exterior, the housing including an external surface facing the exterior and formed from a biocompatible material, a first housing opening in fluid communication with the pump chamber inlet and a second housing opening in fluid communication with the pump chamber outlet.

2. The implant unit of claim 1, wherein

the pump chamber comprises a flexible conduit,

the pump chamber inlet opening and the pump chamber outlet opening comprise walls that are substantially less elastic than the flexible conduit, and

the actuation position is asymmetrically located between the inlet opening and the outlet opening.

3. The implant unit of claim 2, further comprising an electromagnet within the housing, and wherein

the force-transferring member comprises a magnetically-reactive material, and

the electromagnet and the force-transferring member are configured such that the force-transferring member compresses the flexible conduit when power is not applied to the electromagnet and such that compression of the flexible conduit is relieved when power is applied to the electromagnet.

4. The implant unit of claim 2, wherein the housing is elongated and has first and second ends, wherein the first and second housing openings are located at the first end of the housing, and further comprising

a drug reservoir located at the second housing end, the drug reservoir including an internal volume;

and

a first fluid conduit placing the first housing opening in fluid communication with the drug reservoir internal volume along a first fluid path, and wherein

the second housing opening and the drug reservoir internal volume are in fluid communication along a second fluid path, and

the flexible conduit is part of the second fluid path.

5. The implant unit of claim 4, wherein the housing has an outer diameter that does not exceed 10 millimeters.

6. The implant unit of claim 2, wherein the force-transferring member comprises a magnetically-reactive material and is configured to compress the flexible conduit in response to a magnetic field originating from a source external to the implant unit.

7. The implant unit of claim 2, wherein the force-transferring member comprises a magnetically-reactive material, and further comprising electrically conductive windings surrounding the flexible conduit on opposite sides of the force-transferring member.

8. The implant unit of claim 2, further comprising

an electro-reactive actuating element within the housing configured to move the force-transferring member to compress the flexible conduit,

a sealed barrier dividing the housing internal space into a first internal space containing the flexible conduit and the force transferring member and a second internal space containing the electro-reactive actuating element.

9. The implant unit of claim 1, wherein the flexible wall comprises a flexible membrane.

10. The implant unit of claim 1, further comprising a drug reservoir in fluid communication with the pump chamber and containing at least one of a solid drug, a nanoparticle or microparticle mass, or a gel- or liquid-formulated drug.

11. The implant unit of claim 10, wherein the drug reservoir is attached to or contained within the housing.

12. The implant unit of claim 1, further comprising an electro-reactive actuating element configured to move the force-transferring member and at least one implant unit processor configured to activate the electro-reactive actuating element.

13. The implant unit of claim 12, further comprising at least one memory, and wherein the at least one implant unit processor is further configured to activate the electro-reactive actuating element according to multiple dosing sequences stored in the memory, each dosing sequence including a time at which fluid is to be pumped through the pump chamber.

14. The apparatus of claim 13, wherein each dosing sequence further includes a duty cycle corresponding to a number of times the force-transferring member is to be moved during the dosing sequence.

15. The apparatus of claim 14, wherein the at least one implant unit processor is further configured

to wirelessly communicate with at least one external device, and

to modify a dosing sequence stored in the memory in response to a received communication.

16. The apparatus of claim 15, wherein the at least one implant unit processor is further configured

to activate the electro-reactive actuating element in response to an instruction in a received instruction,

to store data corresponding to times at which the electro-reactive actuating element has been activated, and

to wirelessly communicate the stored data to an external device.

17. The apparatus of claim 15, further comprising a battery and a charging coil, and wherein the implant unit is configured to charge the battery using electrical energy output by the coil in response to an applied magnetic field, to receive communications by demodulating magnetic signals received by the coil, and to transmit communications using the coil.

18. The implant unit of claim 13, further comprising a patient interface unit, the patient interface unit having at least one patient interface unit processor configured to perform operations that include

wirelessly communicating instructions to the at least one implant unit processor, after the implant unit is implanted in a living human or other animal, causing activation of the implant unit, and

wirelessly communicating instructions to the at least one implant unit processor, after the implant unit is implanted in a living human or other animal, causing deactivation of the implant unit.

19. The implant unit of claim 18, wherein the patient interface unit comprises a coil, and wherein the patient interface unit is configured to generate a magnetic field with the coil sufficient to charge a battery of the implant unit after the implant unit has been implanted in a living human or other animal.

20. The implant unit of claim 18, wherein the at least one patient interface unit processor is configured to communicate with software executing on a computer separate from the patient interface unit.

21. The implant unit of claim 1, further comprising:

a battery;

a piezoelectric element configured to generate force in response to a drive voltage;

a plurality of voltage stages, each voltage stage configured to receive an input voltage and provide a higher output voltage, each voltage stage comprising a capacitor and a switch network configurable to alternately charge and discharge the capacitor according to a charge cycle for the stage, the voltage stages arranged in series to sequentially increase the input voltage so as to yield a drive voltage greater than a maximum voltage obtainable from the battery alone; and

a timing control sequence circuit configured to control switching of the voltage stage switch networks according to the respective charge cycles, wherein a charge cycle frequency of each voltage stage of the plurality after a first stage in the series is one half the charge cycle frequency of the immediately preceding voltage stage of the series.

22. The implant unit of claim 17, wherein the electro-reactive actuating element comprises a piezoelectric element configured to generate force in response to a drive voltage, and wherein the battery is connected to one side of the charging coil, and further comprising:

a charge capacitor; and

a voltage comparison and switch control circuit configured to, according to a constant duty cycle, alternately energize the charging coil with the battery and de-energize the charging coil so as to charge the charge capacitor.

23. An implant unit, comprising:

a housing sized for implantation into the body of a living human and having a biocompatible exterior;

a valveless impedance pump contained within the housing;

a drug reservoir, in fluid communication with the valveless impedance pump, containing a supply of solid drug removable by flow of vehicle passing through the valveless impedance pump and the drug reservoir;

a first fluid conduit in fluid communication with one of the valveless impedance pump and the drug reservoir;

a second fluid conduit in fluid communication with the other of the valveless impedance pump and the drug reservoir; and

a third fluid conduit in placing the valveless impedance pump in fluid communication with the drug reservoir.

24. The implant unit of claim 23, wherein the drug reservoir is contained in the housing.

25. The implant unit of claim 23, further comprising:

an actuator configured to cause compression of a flexible wall of a fluid chamber of the valveless impedance pump in response to an applied electrical power;

a battery;

a coil configured to output electrical energy in response to a magnetic field applied by an external source; and

control electronics configured to control the actuator, to control charging of the battery from the electrical energy output by the coil, and configured to receive communications from an external device via the coil.

26. A patient interface unit, comprising:

a display; and

at least one processor configured to wirelessly communicate, to a drug delivery implant unit after the drug delivery implant unit has been implanted into a living human or other animal,

an activation instruction,

a deactivation instruction, and

instructions to modify at least one of the following

scheduled future times at which the drug delivery implant unit will activate a drug delivery pump to commence a drug delivery sequence, and

the duration of a future drug delivery sequence.

27. The patient interface unit of claim 26, wherein the at least one processor is further configured to download data from a drug delivery implant unit after the implant unit has been implanted into a living human or other animal.

28. The patient interface unit of claim 26, wherein the at least one processor is further configured to communicate with software executing on a separate computer and receive program instructions from the software, and wherein the program instructions include instructions limiting instructions that the at least one processor can communicate to an implanted drug delivery implant unit.